357Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
United Kingdom
Neuroscience Intelligence
United Kingdom neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #3 of 50 · Data maturity A · Research score 51.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
83Recruiting trials
1,521Publications
728Institutions
Executive interpretation
United Kingdom ranks #3 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
University of Oxford184 recruiting
Hoffmann-La Roche185 recruiting
Merck Sharp & Dohme LLC156 recruiting
University College, London132 recruiting
King's College London112 recruiting
University of Nottingham83 recruiting
Eisai Inc.62 recruiting
AbbVie51 recruiting
UCB Pharma50 recruiting
Eli Lilly and Company50 recruiting
Disease activity
Parkinsons56trials
Alzheimers56trials
Epilepsy47trials
Other Neurology19trials
Depression18trials
Neuromuscular16trials
Stroke15trials
Autism13trials
Adhd13trials
Multiple Sclerosis11trials
Research institutions
Royal Gwent HospitalOpenAlexlinked institution
Aneurin Bevan University Health BoardOpenAlexlinked institution
Northumbria Healthcare NHS Foundation TrustOpenAlexlinked institution
Coventry and Warwickshire Partnership NHS TrustOpenAlexlinked institution
University Hospitals Birmingham NHS Foundation TrustOpenAlexlinked institution
Genomics EnglandOpenAlexlinked institution
Amgen (United Kingdom)OpenAlexlinked institution
Oxford Brookes UniversityOpenAlexlinked institution
Scottish Universities Environmental Research CentreOpenAlexlinked institution
World Federation of NeurologyOpenAlexlinked institution
Clinical evidence trail
NCT07786116The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological ConditionsRECRUITING
NCT07781345A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)NOT_YET_RECRUITING
NCT07724132An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's DiseaseRECRUITING
NCT07389447Focused Ultrasound Stimulation of the Cerebellum to Induce Changes in Cognition and Brain ActivityACTIVE_NOT_RECRUITING
NCT07339423AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightRECRUITING
NCT07265362Compassion Focussed Therapy Informed Psychoeducation and Loving Kindness Meditation for Young People With EpilepsyNOT_YET_RECRUITING
NCT07261033Exploring Equine-Assisted Psychotherapy as an Intervention for Those Who Have Received a Diagnosis of Emotionally Unstable Personality DisorderACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDMultifunctional theranostic nanocarrier platform for microglia-selective cytochalasin D delivery to modulate neuroinflammation after acute brain injuries.2027-02-01
PUBMEDLithium and quetiapine augmentation therapy in treatment-resistant depression with atypical features.2026-12-01
PUBMEDIdentifying differential interactions of potentially traumatic experiences with genetic risk for posttraumatic stress disorder.2026-12-01
PUBMEDPrevalence of exposure to lifetime and war-related traumas, PTSD and complex PTSD in a sample from the Ukrainian general population.2026-12-01
PUBMEDGenetic and environmental origins of the co-occurrence of autistic traits, anxiety and depression: Evidence from meta-analysis and twin study.2026-12-01
PUBMEDEye Movement Desensitisation and Reprocessing (EMDR) for ICU-related psychological distress among adult intensive care survivors: a scoping review.2026-12-01
PUBMEDPost-resettlement context matters: a qualitative study of refugee parents' responses to child trauma in low-resource settings.2026-12-01
PUBMEDEvaluating the association between potentially morally injurious events (PMIEs) and types of psychological distress. A systematic review.2026-12-01
PUBMEDSustained cognitive and functional effects of pro-cognitive interventions for bipolar disorder: A systematic review of randomised controlled trials.2026-12-01
PUBMEDTargeting depression before it starts: An updated systematic review and meta-analysis of preventive interventions in young adults from randomized controlled trials.2026-12-01
PUBMEDEffect of Fenfluramine on convulsive seizures and rescue medication usage: A case series of adults within the Lennox-Gastaut syndrome spectrum.2026-12-01
PUBMEDPsychomotor retardation and risk of Parkinson's disease in unipolar depression: A retrospective cohort study.2026-12-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.